Chinese drug developer Sichuan Biokin Pharmaceutical has postponed its Hong Kong share listing, which had been scheduled to begin on Monday, as enthusiasm for initial public offerings (IPOs) in the sector may be cooling, according to analysts. The company cited “prevailing market conditions” in a stock-exchange filing on Wednesday and said it was assessing an updated timetable, but did not provide further details. The decision “does not affect the company’s current business”, it added. Listed in…
You must log in or # to comment.